Referenties

Saxenda® Liraglutide

Op deze pagina vind je een uitgebreide lijst met wetenschappelijke referenties die gebruikt zijn voor de artikelen in onze FAQ-sectie over Saxenda® (liraglutide). Deze bronnen zijn zorgvuldig geselecteerd via gerenommeerde databases zoals PubMed en andere wetenschappelijke platforms. De referenties zijn afkomstig uit vooraanstaande medische tijdschriften, wetenschappelijke publicaties en officiële gebruiksinstructies. Ze bieden een diepgaand inzicht in de effectiviteit, veiligheid en toepassing van Saxenda® bij gewichtsmanagement.

Referenties

1. Dose Response Effects of Liraglutide (Saxenda) on Weight Loss among Overweight and Obese Individuals (2024). Athens Journal of Health. Beschikbaar op: https://www.athensjournals.gr/health/2024-11-1-4-Rajar.pdf

2. Medications for Obesity: A Review (2024). Journal of the American Medical Association. Beschikbaar op: https://pubmed.ncbi.nlm.nih.gov/39037780/

3. Real‐Life Use of Liraglutide 3 mg in Obesity Management: The SAX‐RL Study (2024). Diabetes, Obesity and Metabolism. Beschikbaar op: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15845

4. Liraglutide 3.0 mg (Saxenda) for Weight Loss and Remission of Pre-Diabetes (2024). Obesity Surgery. Beschikbaar op: https://link.springer.com/article/10.1007/s11695-023-06895-7

5. Liraglutide (Saxenda) Combined with Lifestyle Coaching for Weight Loss in a Bariatric Center (2024). Journal of Surgery. Beschikbaar op: https://journalonsurgery.org/articles/js-v4-1157.html

6. One-Year Weight Reduction with Semaglutide or Liraglutide in Clinical Practice (2024). JAMA Network Open. Beschikbaar op: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823644

7. Saxenda, Werkzame stof: liraglutide (2024). Apotheek.nl. Beschikbaar op: https://www.apotheek.nl/medicijnen/liraglutide?product=saxenda

8. Saxenda (2024). Novo Nordisk. Beschikbaar op: https://www.saxenda.com/

9. Highlights of Prescribing Information (2024). Novo Nordisk. Beschikbaar op: https://www.novo-pi.com/saxenda.pdf

10. Prikinstructies (2024). Novo Nordisk. Beschikbaar op: https://www.saxenda.com/about-saxenda/how-to-use-the-pen.html

11. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism (2024). Diabetes & Metabolism Journal. Beschikbaar op: https://www.e-dmj.org/journal/view.php?number=2843

12. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis (2024). Therapeutic Advances in Neurological Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437580/

13. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks (2024). Obesity Pillars Journal. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/

14. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (2024). Diabetes Care. Beschikbaar op: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2

15. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/

16. Glucagon‐like peptide‐1 receptor agonists and kidney outcomes (2024). Journal of Diabetes. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11450654/

17. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide (2024). Cardiovascular Diabetology. Beschikbaar op: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02319-7

18. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Beschikbaar op: https://www.bmj.com/content/384/bmj-2023-076410.long

19. Productkenmerken (2024). Novo Nordisk. Beschikbaar op: https://www.ema.europa.eu/nl/documents/product-information/saxenda-epar-product-information_nl.pdf

20. Medications for the Treatment of Obesity (2023). Journal of Visceral Surgery. Beschikbaar op: https://www.sciencedirect.com/science/article/abs/pii/S187878862200176X

21. Obesity Management in Adults A Review (2023). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/

22. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications (2023). Life. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10144237/

23. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/

24. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial (2023). Cardiovascular Diabetology. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9960425/

25. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes (2023). Diabetes, Obesity and Metabolism. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10544709/

26. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues (2023). Reviews in Endocrine and Metabolic Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/

27. Glucagon‐like peptide agonists: A prospective review (2023). Endocrinology, Diabetes & Metabolism. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10782143/

28. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext

29. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2810542

30. Obesity Management in Adults A Review (2023). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/

31. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2023). American Pharmacists Association. Beschikbaar op: https://www.sciencedirect.com/science/article/pii/S1544319123003096

32. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/

33. The Effects and Side Effects of Liraglutide as a Treatment for Obesity (2022). Cardiovascular Prevention and Health. Beschikbaar op: https://synapse.koreamed.org/articles/1516079546

34. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight (2022). Clinical Epidemiology. Beschikbaar op: https://www.dovepress.com/efficacy-and-safety-of-liraglutide-and-semaglutide-on-weight-loss-in-p-peer-reviewed-fulltext-article-CLEP

35. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults (2022). Journal of the American Medical Association. Beschikbaar op: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753508/

36. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (2022). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC8753508/

37. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review (2022). Clinical Epidemiology. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9738168/

38. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022). Nature Communications. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9378667/

39. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review (2022). Therapeutic Advances in Chronic Disease. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9260566/

40. Factors associated with successful weight loss after liraglutide treatment for obesity (2022). Diabetes, Obesity and Metabolism. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9812862/

41. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392

42. Effects of Liraglutide on Gastrointestinal Functions and Weight in Obesity: A Randomized Clinical and Pharmacogenomic Trial (2022). Obesity. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9335902/

43. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022). Nature. Beschikbaar op: https://www.nature.com/articles/s41467-022-32307-y

44. Effects of Liraglutide on Visceral and Ectopic Fat in Adults with Overweight and Obesity (2021). The Lancet Diabetes & Endocrinology. Beschikbaar op: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00179-0/abstract

45. Energy Intake as a Short‐Term Biomarker for Weight Loss in Adults with Obesity Receiving Liraglutide (2021). Obesity Science & Practice. Beschikbaar op: https://onlinelibrary.wiley.com/doi/10.1002/osp4.486

46. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021). New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

47. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists (2021). Advances in Therapy. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC8189979/#Abs1

48. Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis (2021). eClinicalMedicine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC8633575/

49. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists (2021). Advances in Therapy. Beschikbaar op: https://link.springer.com/article/10.1007/s12325-021-01710-0

50. Productkenmerken (2020). Novo Nordisk. Beschikbaar op: https://www.ema.europa.eu/nl/documents/product-information/saxenda-epar-product-information_nl.pdf

51. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial (2020). Obesity. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC7065111/

52. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial (2020). Diabetes Care. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC7171937/

53. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial (2020). Diabetes Care. Beschikbaar op: https://diabetesjournals.org/care/article/43/5/1085/35698/Efficacy-and-Safety-of-Liraglutide-3-0-mg-in

54. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial (2020). Obesity. Beschikbaar op: https://onlinelibrary.wiley.com/doi/10.1002/oby.22726

55. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance (2020). Clinical Diabetes. Beschikbaar op: https://diabetesjournals.org/clinical/article/38/4/390/35426/Switching-Between-Glucagon-Like-Peptide-1-Receptor

DISCLAIMER

Betrouwbare informatie, verantwoord gedeeld

Samen op weg naar een gezonder leven – veilig, effectief en afgestemd op jouw doelen

De inhoud van deze referentielijst is uitsluitend bedoeld voor informatieve doeleinden. De vermelde artikelen en bronnen zijn gebaseerd op openbare wetenschappelijke publicaties en hebben betrekking op het gebruik van Saxendac® en gerelateerde behandelingen. Hoewel we hebben gestreefd naar nauwkeurigheid en volledigheid, raden we aan om professioneel medisch advies in te winnen voordat u beslissingen neemt op basis van de inhoud van deze referenties. BMI Clinic aanvaardt geen aansprakelijkheid voor eventuele onjuistheden of onvolledigheden in de verstrekte informatie.

Voor meer achtergrondinformatie kan je de uitgebreide lijst op de pagina ‘Bronnen‘ raadplegen.